NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018
This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.
![](http://aardexgroup.com/wp-content/uploads/2019/08/medicines.jpg)
NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018
This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.
Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance
In a clinical trial, every piece of data contributes to the overall story being told. No matter how small or seemingly insignificant, all the information that emerges over the course of the process adds rich detail to the narrative. Two